Ceramides and Ceramide Scores: Clinical Applications for Cardiometabolic Risk Stratification.
cardiovascular disease
ceramide
ceramide score
coronary heart disease
diabetes mellitus
heart failure
stroke
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
06
2020
accepted:
27
08
2020
entrez:
2
11
2020
pubmed:
3
11
2020
medline:
22
5
2021
Statut:
epublish
Résumé
Ceramides are bioactive lipids that have an important role in many cellular functions such as apoptosis and inflammation. During the past decade emerging clinical data have shown that ceramides are not only of great biochemical interest but may also have diagnostic utility. Ceramides have shown independent predictive value for negative cardiovascular outcomes as well as for the onset of type 2 diabetes. Based on abundant published data, risk score using the concentrations of circulating ceramides have been developed and adapted for routine clinical practice. Currently serum ceramides are used clinically as efficient risk stratifiers for primary and secondary prevention of atherosclerotic cardiovascular disease (CVD). A direct cause-effect relationship between CVD and ceramide has not been established to date. As ceramide-specific medications are being developed, conventional strategies such as lipid lowering agents and lifestyle interventions can be used to reduce overall risk. Ceramides can identify a very high-risk coronary heart disease category of patients in need for more intense medical attention, specifically those patients at higher risk as highlighted in the 2019 European Society of Cardiology guidelines for stable chronic coronary syndrome patients. In addition, the ceramide risk score may be used as a decision-making tool in primary prevention patients with moderate CVD risk. Finally, the ceramide risk score may have a unique utility as a motivational tool to increase patient's adherence to medical therapy and lifestyle changes.
Identifiants
pubmed: 33133018
doi: 10.3389/fendo.2020.570628
pmc: PMC7550651
doi:
Substances chimiques
Biomarkers
0
Ceramides
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
570628Informations de copyright
Copyright © 2020 Hilvo, Vasile, Donato, Hurme and Laaksonen.
Références
Diabetes Metab. 2018 Mar;44(2):143-149
pubmed: 28499696
J Am Heart Assoc. 2018 May 3;7(10):
pubmed: 29728014
Circ J. 2017 Nov 24;81(12):1886-1893
pubmed: 28674269
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
Pharmacol Res. 2008 Jul;58(1):45-51
pubmed: 18611440
Trends Endocrinol Metab. 2015 Oct;26(10):538-550
pubmed: 26412155
Atherosclerosis. 2018 Feb;269:159-165
pubmed: 29366988
Brain Res Bull. 2020 May;158:122-127
pubmed: 32165273
Diabetes Metab Res Rev. 2015 Oct;31(7):734-44
pubmed: 25959529
J Biol Chem. 2005 Mar 18;280(11):10284-9
pubmed: 15590644
Biochim Biophys Acta. 2005 Oct 15;1737(1):44-51
pubmed: 16216550
Adv Exp Med Biol. 2019;1161:169-191
pubmed: 31562630
Circulation. 2019 Jun 18;139(25):e1082-e1143
pubmed: 30586774
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
Front Endocrinol (Lausanne). 2019 Aug 21;10:577
pubmed: 31496996
Arterioscler Thromb Vasc Biol. 2016 Dec;36(12):2424-2430
pubmed: 27765765
Anticancer Agents Med Chem. 2012 May;12(4):340-63
pubmed: 21707511
JAMA. 1986 Nov 28;256(20):2823-8
pubmed: 3773199
Sci Rep. 2018 May 8;8(1):7249
pubmed: 29739997
Prog Lipid Res. 2014 Apr;54:53-67
pubmed: 24513486
Eur Heart J. 2016 Jul 01;37(25):1967-76
pubmed: 27125947
Physiol Rep. 2017 Jul;5(13):
pubmed: 28694327
J Clin Endocrinol Metab. 2014 Nov;99(11):E2335-40
pubmed: 25140396
J Am Coll Cardiol. 2020 Mar 24;75(11):1249-1262
pubmed: 32192650
Diabet Med. 2020 Jan;37(1):11-19
pubmed: 30803019
J Am Heart Assoc. 2016 Oct 13;5(10):
pubmed: 27737874
Circ Heart Fail. 2019 Jul;12(7):e005708
pubmed: 31296099
Nat Rev Endocrinol. 2020 Apr;16(4):224-233
pubmed: 32060415
Circulation. 2017 May 23;135(21):2028-2040
pubmed: 28280233
J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264
pubmed: 30153967
J Am Heart Assoc. 2020 May 18;9(10):e015258
pubmed: 32375553
JACC Cardiovasc Imaging. 2017 Aug;10(8):923-937
pubmed: 28797416
J Lipid Res. 2018 Sep;59(9):1729-1737
pubmed: 29858423
J Gerontol A Biol Sci Med Sci. 2020 Sep 16;75(9):1663-1670
pubmed: 32215553
Lipids Health Dis. 2013 Jul 08;12:98
pubmed: 23835113
J Clin Invest. 2020 Mar 2;130(3):1363-1376
pubmed: 31743112
Eur Heart J. 2020 Jan 14;41(3):371-380
pubmed: 31209498
Obesity (Silver Spring). 2015 Jul;23(7):1414-21
pubmed: 25966363
J Am Coll Cardiol. 2019 Aug 27;74(8):1057-1068
pubmed: 31439215
J Clin Endocrinol Metab. 2014 Jan;99(1):E45-52
pubmed: 24243630
Biochem Pharmacol. 2005 Apr 15;69(8):1195-204
pubmed: 15794940
Circulation. 2018 Aug 21;138(8):756-766
pubmed: 29626068
J Endocrinol. 2017 Jun;233(3):329-340
pubmed: 28522731
Int J Mol Sci. 2020 Feb 22;21(4):
pubmed: 32098447
Diabetes Care. 2003 Dec;26(12):3230-6
pubmed: 14633807
JCI Insight. 2018 Sep 6;3(17):
pubmed: 30185661
Diabetes Care. 2018 Aug;41(8):1732-1739
pubmed: 29844096
Science. 2019 Jul 26;365(6451):386-392
pubmed: 31273070
Eur Heart J. 2020 Jan 14;41(3):407-477
pubmed: 31504439
Cell Rep. 2017 Feb 28;18(9):2269-2279
pubmed: 28249170
Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):2723-32
pubmed: 21903946
Neurol Neurochir Pol. 2019;53(6):484-491
pubmed: 31804702
Diabetologia. 2018 Jun;61(6):1424-1434
pubmed: 29546476
Diabetes. 2018 Aug;67(8):1663-1672
pubmed: 29588286
Prog Lipid Res. 2016 Jan;61:51-62
pubmed: 26703189
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Diabetologia. 2018 Dec;61(12):2570-2579
pubmed: 30159588
Ann Intern Med. 1971 Jan;74(1):1-12
pubmed: 5539274
J Cardiovasc Transl Res. 2020 Mar 24;:
pubmed: 32212040